Cargando…
Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
Metastatic colorectal cancer (mCRC) is a prevalent disease for which combination cytotoxic chemotherapy is the mainstay of treatment. With the use of targeted therapy, including anti-angiogenic agents, there have been significant improvements in overall outcome of patients with mCRC. Bevacizumab, a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300250/ https://www.ncbi.nlm.nih.gov/pubmed/28190957 http://dx.doi.org/10.2147/GICTT.S97740 |